MedTrace Logo

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

NCT02026401 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.

Conditions

  • Primary Biliary Cirrhosis

Interventions

BIOLOGICAL

NGM282

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • NGM Biopharmaceuticals Australia Pty Ltd

    collaborator INDUSTRY

  • NGM Biopharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Stephen J Rossi, PharmD · NGM Biopharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02026401 on ClinicalTrials.gov